Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ELIQUIS, which is being developed by the alliance of Bristol-Myers Squibb and Pfizer, has received the European Commission approval for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
Subscribe to our email newsletter
The approval is based on the ADVANCE-2 and ADVANCE-3 clinical trials, part of the EXPANSE clinical trial program.
ELIQUIS is an oral anticoagulant with a 12- to 24-hour post surgery initiation window, which aids physicians to monitor and stabilize post-surgical patients before beginning treatment.
In these trials, ELIQUIS given orally twice daily demonstrated efficacy versus enoxaparin 40 mg given once daily by injection in the prevention of VTE in total knee and total hip replacement, and did not increase the risk of bleeding versus enoxaparin.
ELIQUIS Phase 3 orthopedic trials lead investigator Michael Rud Lassen said the approval of ELIQUIS gives European orthopedic surgeons a new option in VTE prevention that is effective than the current standard of care, enoxaparin 40 mg once daily, and importantly, without increasing bleeding.